Business
Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
NEW HAVEN, Conn., February 05, 2026--Veradermics, Incorporated ("Veradermics"), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the closing of its previously announced upsized initial public offering of 17,339,294 shares of its common stock at an initial public offering price of $17.00 per share, including 2,261,647 shares sold pursuant to the exer
About this update from Veradermics, Incorporated
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1500,"height":450,"url":"https://media.zenfs.com/en/business-wire.com/1315b71c3e7223e1668194eef16cae2a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V3KpwdE15eYNMFVEHVtOHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1315b71c3e7223e1668194eef16cae2a","width":960,"height":288},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/SxAOC1MwCqAdAMRRLz1VYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/1315b71c3e7223e1668194eef16cae2a","width":1200,"height":360}},"lazy":false},{"type":"text","content":"NEW HAVEN, Conn., February 05, 2026--(BUSINESS WIRE)--Veradermics, Incorporated ("Veradermics"), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the closing of its previously announced upsized initial public offering of 17,339,294 shares of its common stock at an initial public offering price of $17.00 per share, including 2,261,647 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from the offering were approximately $294.8 million, before deducting underwriting discount and commissions and estimated offering expenses. All of the shares were sold by Veradermics. Veradermics shares began trading on the New York Stock Exchange on February 4, 2026 under the ticker symbol "MANE".","length":928,"tagName":"p"},{"type":"text","content":"Jefferies, Leerink Partners, Citigroup, and Cantor are acting as joint book-running managers for the offering.","length":110,"tagName":"p"},{"type":"text","content":"Registration statements relating to the shares being sold in the offering have been filed with the U.S. Securities and Exchange Commission ("SEC") and are effective. The offering was made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Departm...